标签归档：by

彼爱姆BM-22BY荧光显微镜UIS

发表于由

彼爱姆BM-22BY荧光显微镜UIS

  • 品牌 彼爱姆|BM
  • 型号 BM-22BY
  • 商品详情

    产品介绍

    BM-22BY落射荧光显微镜是一种多用途光学仪器，采用无放大率色差的无限远平场消色差荧光物镜和大视野目镜,光学系统成像清晰,视野广阔。

    激发光源采用大功率高亮度单色LED模块组，透射光源采用大功率高亮度白光LED模块，照明亮度可调

    照明装置功耗小，使用寿命长，具有安全、舒适等操作性能。是生命科学领域研究、疾病预防与免疫检测的理想仪器

    可供科研、高校、医疗和疾控防疫等部门使用。

    技术规格

    目镜

    类 别 放大倍数 视场直径(mm)
    超宽视场平场目镜 10X Φ22

    物镜

    类 别 放大倍数 数值孔径（NA） 工作距离（mm）
    无限远平场消色差物镜 4X 0.10 19.80
    10X 0.25 5.0
    40X 0.85 0.42
    100X(油) 1.25 0.36

    3、放大倍数：

    物 镜 目 镜 镜筒系数 总放大倍数
    4X 10X 1X 40X
    10X 100X
    40X 400X
    100X 1000X

    4、机械筒长：无限远系统(∞)

    5、物镜转换器：内倾式内定位五孔转换器

    6、调焦装置：粗微动同轴调焦,，微动格值0.002mm，带锁紧和限位装置

    7、载物台：双层机械移动，尺寸：210mm x 140mm；移动范围：75mm x 50mm

    8、聚光镜： 阿贝聚光镜 NA.1.25，可上下升降

    9、滤色片：蓝色、磨砂玻璃

    10、荧光装置，激发组：

    蓝（B）激发波长：410-490，发射波长：515nm

    绿（G）激发波长：475-550，发射波长：595nm

    11、光源：落射荧光照明：3W高亮LED

    透射照明：集光器，3W高亮白光LED, 亮度可调

    • Pantoprazole(Synonyms: 泮托拉唑; BY1023; SKF96022)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Pantoprazole (Synonyms: 泮托拉唑; BY1023; SKF96022)

    Pantoprazole (BY1023) 是一种具有口服活性的，有效质子泵 (proton pump) 抑制剂 (PPI)。Pantoprazole 是一种取代的苯并咪唑，是一种有效的 H+/K+-ATPase 抑制剂，IC50 为 6.8 μM。Pantoprazo 可以改善 pH 值稳定性，并具有抗分泌，抗溃疡的作用。Pantoprazo 联合阿霉素 (Doxorubicin; HY-15142) 可显着增加肿瘤生长延迟。

    Pantoprazole(Synonyms: 泮托拉唑; BY1023; SKF96022)

    Pantoprazole Chemical Structure

    CAS No. : 102625-70-7

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    Pantoprazole 的其他形式现货产品:

    Pantoprazole sodium Pantoprazole sodium hydrate

    生物活性

    Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

    IC50 & Target

    proton pump
    体外研究
    (In Vitro)

    Pantoprazole (BY1023; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells[1].
    Pantoprazole (BY10232) can block exosome release. Pantoprazole (BY10232) inhibits the activity of V-H+-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium[2]

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    Pantoprazole (BY1023; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin[1].
    Pantoprazole (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats[4].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Mice bearing MCF-7 or A431 xenografts[1]
    Dosage: 200 mg/kg
    Administration: IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.)
    Result: Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
    Significantly increased tumor growth delay with a single dose with Doxorubicin.
    There is no effect on growth delay alone.

    Clinical Trial

    分子量

    383.37

    Formula

    C16H15F2N3O4S
    CAS 号

    102625-70-7
    中文名称

    泮托拉唑
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Krupa J Patel, et al. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013 Dec 15;19(24):6766-76.

      [2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

      [3]. W Beil, et al. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability. Eur J Pharmacol. 1992 Aug 6;218(2-3):265-71.

      [4]. K Takeuchi, et al. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    Pantoprazole(Synonyms: 泮托拉唑; BY1023; SKF96022)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Pantoprazole (Synonyms: 泮托拉唑; BY1023; SKF96022)

    Pantoprazole (BY1023) 是一种具有口服活性的，有效质子泵 (proton pump) 抑制剂 (PPI)。Pantoprazole 是一种取代的苯并咪唑，是一种有效的 H+/K+-ATPase 抑制剂，IC50 为 6.8 μM。Pantoprazo 可以改善 pH 值稳定性，并具有抗分泌，抗溃疡的作用。Pantoprazo 联合阿霉素 (Doxorubicin; HY-15142) 可显着增加肿瘤生长延迟。

    Pantoprazole(Synonyms: 泮托拉唑; BY1023; SKF96022)

    Pantoprazole Chemical Structure

    CAS No. : 102625-70-7

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    Pantoprazole 的其他形式现货产品:

    Pantoprazole sodium Pantoprazole sodium hydrate

    生物活性

    Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

    IC50 & Target

    proton pump
    体外研究
    (In Vitro)

    Pantoprazole (BY1023; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells[1].
    Pantoprazole (BY10232) can block exosome release. Pantoprazole (BY10232) inhibits the activity of V-H+-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium[2]

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    Pantoprazole (BY1023; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin[1].
    Pantoprazole (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats[4].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Mice bearing MCF-7 or A431 xenografts[1]
    Dosage: 200 mg/kg
    Administration: IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.)
    Result: Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
    Significantly increased tumor growth delay with a single dose with Doxorubicin.
    There is no effect on growth delay alone.

    Clinical Trial

    分子量

    383.37

    Formula

    C16H15F2N3O4S
    CAS 号

    102625-70-7
    中文名称

    泮托拉唑
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Krupa J Patel, et al. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013 Dec 15;19(24):6766-76.

      [2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

      [3]. W Beil, et al. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability. Eur J Pharmacol. 1992 Aug 6;218(2-3):265-71.

      [4]. K Takeuchi, et al. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    Pantoprazole(Synonyms: 泮托拉唑; BY1023; SKF96022)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Pantoprazole (Synonyms: 泮托拉唑; BY1023; SKF96022)

    Pantoprazole (BY1023) 是一种具有口服活性的，有效质子泵 (proton pump) 抑制剂 (PPI)。Pantoprazole 是一种取代的苯并咪唑，是一种有效的 H+/K+-ATPase 抑制剂，IC50 为 6.8 μM。Pantoprazo 可以改善 pH 值稳定性，并具有抗分泌，抗溃疡的作用。Pantoprazo 联合阿霉素 (Doxorubicin; HY-15142) 可显着增加肿瘤生长延迟。

    Pantoprazole(Synonyms: 泮托拉唑; BY1023; SKF96022)

    Pantoprazole Chemical Structure

    CAS No. : 102625-70-7

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    Pantoprazole 的其他形式现货产品:

    Pantoprazole sodium Pantoprazole sodium hydrate

    生物活性

    Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

    IC50 & Target

    proton pump
    体外研究
    (In Vitro)

    Pantoprazole (BY1023; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells[1].
    Pantoprazole (BY10232) can block exosome release. Pantoprazole (BY10232) inhibits the activity of V-H+-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium[2]

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    Pantoprazole (BY1023; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin[1].
    Pantoprazole (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats[4].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Mice bearing MCF-7 or A431 xenografts[1]
    Dosage: 200 mg/kg
    Administration: IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.)
    Result: Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
    Significantly increased tumor growth delay with a single dose with Doxorubicin.
    There is no effect on growth delay alone.

    Clinical Trial

    分子量

    383.37

    Formula

    C16H15F2N3O4S
    CAS 号

    102625-70-7
    中文名称

    泮托拉唑
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Krupa J Patel, et al. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013 Dec 15;19(24):6766-76.

      [2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

      [3]. W Beil, et al. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability. Eur J Pharmacol. 1992 Aug 6;218(2-3):265-71.

      [4]. K Takeuchi, et al. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    BY27

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    BY27 

    BY27 是一种有效、选择性的 BET BD2 抑制剂，对 BRD2，BRD3，BRD4 和 BRDT 的 BD2 结构域的选择性分别是 BD1 的 38、5、7 和 21 倍。BY27 具有抗癌作用。

    BY27

    BY27 Chemical Structure

    CAS No. : 2247236-59-3

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    BY27 is a potent and selective BET BD2 inhibitor, shows 38, 5, 7, and 21-fold BD1/BD2 selectivity for BRD2, BRD3, BRD4, and BRDT. Anti-cancer activity[1].

    IC50 & Target[1]

    BRD2 BD2

    3.1 nM (Ki)

    BRD2 BD1

    95.5 nM (Ki)

    BRD3 BD2

    5.3 nM (Ki)

    BRD3 BD1

    77.9 nM (Ki)

    BRD4 BD2

    7.3 nM (Ki)

    BRD4 BD1

    80 nM (Ki)

    BRD2 BD2

    1.2 nM (Kd)

    BRD2 BD1

    45 nM (Kd)

    BRD3 BD2

    2.6 nM (Kd)

    BRD3 BD1

    12 nM (Kd)

    BRD4 BD2

    3.5 nM (Kd)

    BRD4 BD1

    26 nM (Kd)

    BRDT BD2

    3 nM (Kd)

    BRDT BD1

    64 nM (Kd)

    分子量

    404.90

    Formula

    C22H21ClN6
    CAS 号

    2247236-59-3
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Chen D, et al. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins. Eur J Med Chem. 2019 Aug 21;182:111633.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务